Should I Buy LFCR? LFCR 2026 Analysis

Should You Buy Lifecore Biomedical Inc (LFCR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

8.510

1 Day change

-0.58%

52 Week Range

8.980

Analysis Updated At

2026/01/26

Lifecore Biomedical Inc (LFCR) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the technical indicators show some bullish trends, the lack of significant positive catalysts, weak financial performance, and absence of proprietary trading signals suggest holding off on making an investment right now.

Technical Analysis

The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200) and a positive MACD histogram (0.0745), indicating an upward trend. However, the RSI is neutral at 78.561, and the stock is near its resistance level (R1: 8.592). The short-term stock trend analysis predicts a slight decline in the next day and week, with a modest gain of 2.08% in the next month.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

The company's gross margin increased by 14.81% YoY in Q1 2026, and revenue grew by 25.92% YoY, indicating some operational improvements.

Neutral/Negative Catalysts

Net income dropped by -32.76% YoY, and EPS declined by -45.28% YoY, reflecting poor profitability. Additionally, there are no significant hedge fund or insider trading trends, and no recent congress trading data. The news sentiment is unrelated to LFCR and does not provide any positive event-driven catalysts.

Financial Performance

In Q1 2026, revenue increased to $31.1M (up 25.92% YoY), but net income dropped to -$10.91M (down -32.76% YoY). EPS fell to -0.29 (down -45.28% YoY). Gross margin improved to 25.04% (up 14.81% YoY), but overall profitability remains weak.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target data available for LFCR.

Analyst Rating

Wall Street analysts forecast LFCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LFCR is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 8.560

Low

Averages

High

Current: 8.560

Low

Averages

High

KeyBanc

Sector Weight

initiated

AI Analysis

2025-09-04

Reason

KeyBanc

Price Target

AI Analysis

2025-09-04

initiated

Sector Weight

Reason

KeyBanc initiated coverage of Lifecore with a Sector Weight rating and no price target. While the shares trade at a a "relatively modest" multiple, meaningful valuation expansion will require new program wins or contractual step-ups, the analyst tells investors in a research note. The firm says Lifecore's pipeline is transitioning to faster growing markets.

William Blair

Outperform

initiated

2025-05-21

Reason

William Blair

Price Target

2025-05-21

initiated

Outperform

Reason

William Blair initiated coverage of Lifecore (LFCR) with an Outperform rating. Minimum volume commitments from Alcon (ALC) represent "a solid foundation for Lifecore's achievable midterm revenue guide," says the analyst, who projects revenue will grow at an 11.6% compound annual rate from FY25 to FY28, consistent with Lifecore's guidance.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LFCR

Unlock Now

LFCR Should I Buy

LFCR Should I Buy

Should You Buy Lifecore Biomedical Inc (LFCR) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch